Gout in Dalarna, Sweden – a population-based study of gout occurrence and compliance to treatment guidelines
Authors' conclusion
Incidence and prevalence were slightly higher than in previous Swedish reports. Allopurinol use among prevalent gout patients did not increase during 2014-2019. Only a minor improvement in persistence was seen, and a moderate increase in compliance with guidelines
Study context
- Population
- Gout patients in Dalarna, Sweden
- Exposure
- Patients starting allopurinol 2016-2018 vs 2013-2015
- Outcome
- Incidence and prevalence of gout
Methodological detailsprospectively registered data
- Prospectively registered data
Main finding
As reported in the abstract
Incidence of gout during 2014-2019, per 100 000 person-years
221-247
Prevalence in 2018
2.45%
Observational data: associations, not effects.
Further findings
Allopurinol persistence
P = 0.031
Baseline serum urate measured
P < 0.001
Follow-up serum urate measured
P < 0.001
Reaching serum urate < 360 µmol/L
P < 0.001
Proportion of prevalent cases on allopurinol
- Proportion on allopurinol among prevalent cases
- 21% to 25%
Original publication
Gout in Dalarna, Sweden – a population-based study of gout occurrence and compliance to treatment guidelines. Scand J Rheumatol. Published 27 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →